BIOMAT Database Logo BIOMAT Database Logo

Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor. 2007

Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ohgas@pediatr.med.kyushu-u.ac.jp

Regular self-infusion of an activated prothrombin complex concentrate (APCC) has been successfully introduced to a 14-year-old boy with hemophilia A. The child was diagnosed as a neonate, and at age 7 years, developed a high titer (127 BU/mL) factor VIII inhibitor coincident with a protracted ankle joint bleeding. From age 7-10 years, he received on-demand therapy using a prothrombin complex concentrate (PCC), PROPLEX-ST. From age 10-14 years, he received prophylaxis with PROPLEX-ST, initiated after an intracranial hemorrhage and coincident anamnestic inhibitor response. Throughout 7-year period of PCC treatment, he experienced recurrent bleeding episodes. Self-prophylaxis with APCC, FEIBA VH [Anti-inhibitor Coagulant Complex] (50 U/kg/dose three times per week) using infusion pump was initiated at 14 years of age and has continued for 2 years. There were no bleeding, thrombotic events or other adverse events after initiation of this prophylaxis, and inhibitor levels decreased to 1 BU/mL. His quality of life was improved, particularly with respect to school. Our long observation proposes a well-disciplined home-based FEIBA prophylaxis in inhibitor-positive hemophiliacs.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D007592 Joint Diseases Diseases involving the JOINTS. Arthropathies,Arthropathy,Joint Disease
D008297 Male Males
D001779 Blood Coagulation Factors Endogenous substances, usually proteins, that are involved in the blood coagulation process. Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012646 Self Administration Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal. Administration, Self,Administrations, Self,Self Administrations
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses

Related Publications

Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Use of activated prothrombin complex concentrate in a severely hemophilic patient with Factor VIII inhibitor.
April 1983, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor.
November 1976, British medical journal,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Activated prothrombin concentrate for patients with factor VIII inhibitors.
July 1974, The New England journal of medicine,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor.
August 1988, The American journal of medicine,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy.
November 2009, International journal of emergency medicine,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Management of anterior compartment syndrome in two high responder factor VIII inhibitor patients with activated prothrombin complex concentrate.
June 1986, Thrombosis research,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Inhibitor to factor IX following activated prothrombin-complex concentrate treatment.
February 1981, Thrombosis and haemostasis,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.
May 2002, Thrombosis and haemostasis,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level.
February 1979, Thrombosis and haemostasis,
Shouichi Ohga, and Akihiko Nomura, and Hidetoshi Takada, and Naohiro Suga, and Toshiro Hara
Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist Reversal.
June 2018, Critical care medicine,
Copied contents to your clipboard!